{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:18:36Z","timestamp":1791951516869,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prostate cancer (PCa) is a biologically heterogeneous disease that frequently progresses to castration-resistant prostate cancer (CRPC), a challenging clinical stage. The underlying mechanisms driving CRPC progression and resistance to androgen receptor\u00a0(AR) signaling inhibition (ARSI) remain incompletely understood. Emerging evidence implicates the canonical Wnt pathway as a key contributor to CRPC progression. This study elucidates the role of Wnt pathway activation in mediating resistance to ARSI and identifies a robust molecular signature for predicting treatment outcomes. By integrating genomic and transcriptomic data from PCa patients, patient-derived xenografts (PDXs), and experimental models harboring or not Wnt-activating mutations,\u00a0we performed differential expression analysis, unsupervised clustering, survival, and viability analysis to assess Wnt\/\u03b2-catenin pathway activation and its interaction with AR signaling. A specific Wnt transcriptional signature (\n                    <jats:italic>AXIN2<\/jats:italic>\n                    ,\n                    <jats:italic>RNF43<\/jats:italic>\n                    ,\n                    <jats:italic>ZNRF3<\/jats:italic>\n                    ,\n                    <jats:italic>NKD1<\/jats:italic>\n                    ) was found to reliably reflect pathway activation in advanced PCa. AR was found to suppress mutation-driven Wnt signaling, which was upregulated upon AR inhibition, contributing to treatment resistance. Targeting \u03b2-catenin interactions with co-activators p300\/CBP using selective inhibitors (IQ-1 and ICG-001) effectively mitigated Wnt-driven ARSI resistance, restoring sensitivity to therapy in preclinical models. Thus, canonical Wnt pathway activation emerges as a critical mediator of resistance to ARSI in CRPC. The identified Wnt signature holds potential as a biomarker for predicting and monitoring therapeutic outcomes. Concurrent targeting of AR and Wnt signaling represents a promising strategy to overcome treatment resistance, particularly in patients with Wnt-activating mutations.\n                  <\/jats:p>","DOI":"10.1038\/s41418-026-01732-7","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:34:52Z","timestamp":1776134092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of the cross-regulation between Wnt pathway activation and androgen receptor signaling in prostate cancer treatment resistance"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-2623","authenticated-orcid":false,"given":"Nicolas","family":"Anselmino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-8036","authenticated-orcid":false,"given":"Pablo","family":"Sanchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7844-2162","authenticated-orcid":false,"given":"Juan","family":"Bizzotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Labanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D. A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elba S.","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Gueron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6365-1711","authenticated-orcid":false,"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"1732_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"1732_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","volume":"518","author":"A Jamroze","year":"2021","unstructured":"Jamroze A, Chatta G, Tang DG. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance. Cancer Lett. 2021;518:1\u20139.","journal-title":"Cancer Lett"},{"key":"1732_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/annonc\/mdx689","volume":"29","author":"L Wang","year":"2018","unstructured":"Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, et al. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate\u2013prednisone. Ann Oncol. 2018;29:352\u201360.","journal-title":"Ann Oncol"},{"key":"1732_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eururo.2019.05.032","volume":"77","author":"P Isaacsson Velho","year":"2020","unstructured":"Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, et al. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur Urol. 2020;77:14\u201321.","journal-title":"Eur Urol"},{"key":"1732_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1158\/0008-5472.CAN-16-0497","volume":"77","author":"S Nandana","year":"2017","unstructured":"Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, et al. Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis. Cancer Res. 2017;77:1331\u201344.","journal-title":"Cancer Res"},{"key":"1732_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1320-y","volume":"38","author":"A Vall\u00e9e","year":"2019","unstructured":"Vall\u00e9e A, Lecarpentier Y, Vall\u00e9e JN. Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT\/\u03b2-catenin pathway. J Exp Clin Cancer Res. 2019;38:1\u201316.","journal-title":"J Exp Clin Cancer Res"},{"key":"1732_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.01248","volume":"9","author":"Y Lecarpentier","year":"2019","unstructured":"Lecarpentier Y, Schussler O, H\u00e9bert JL, Vall\u00e9e A. Multiple targets of the canonical WNT\/\u03b2-catenin signaling in cancers. Front Oncol. 2019;9:1\u201317.","journal-title":"Front Oncol"},{"key":"1732_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/carcin\/bgr305","volume":"33","author":"RS Tarapore","year":"2012","unstructured":"Tarapore RS, Siddiqui IA, Mukhtar H. Modulation of Wnt\/ -catenin signaling pathway by bioactive food components. Carcinogenesis. 2012;33:483\u201391.","journal-title":"Carcinogenesis"},{"key":"1732_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2018.00170","volume":"6","author":"KS Houschyar","year":"2019","unstructured":"Houschyar KS, Tapking C, Borrelli MR, Popp D, Duscher D, Maan ZN, et al. Wnt pathway in bone repair and regeneration\u2013what do we know so far? Front Cell Dev Biol. 2019;6:1\u201313.","journal-title":"Front Cell Dev Biol"},{"key":"1732_CR10","doi-asserted-by":"crossref","unstructured":"Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol. 2019;3:1\u201323.","DOI":"10.1200\/PO.18.00283"},{"key":"1732_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"1732_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2121-9-4","volume":"9","author":"L Schweizer","year":"2008","unstructured":"Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, Lin TA, et al. The androgen receptor can signal through Wnt\/\u03b2-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol. 2008;9:1\u201315.","journal-title":"BMC Cell Biol"},{"key":"1732_CR13","doi-asserted-by":"publisher","first-page":"e0141589","DOI":"10.1371\/journal.pone.0141589","volume":"10","author":"E Lee","year":"2015","unstructured":"Lee E, Ha S, Logan SK. Divergent androgen receptor and beta-catenin signaling in prostate cancer cells. PLoS ONE. 2015;10:e0141589.","journal-title":"PLoS ONE"},{"key":"1732_CR14","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/jid.2015.242","volume":"135","author":"K Kretzschmar","year":"2015","unstructured":"Kretzschmar K, Cottle DL, Schweiger PJ, Watt FM. The androgen receptor antagonizes Wnt\/\u03b2-catenin signaling in epidermal stem cells. J Investig Dermatol. 2015;135:2753\u201363.","journal-title":"J Investig Dermatol"},{"key":"1732_CR15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"1732_CR16","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1158\/1078-0432.CCR-23-2438","volume":"30","author":"N Anselmino","year":"2024","unstructured":"Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, et al. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clin Cancer Res. 2024;30:2272\u201385.","journal-title":"Clin Cancer Res"},{"key":"1732_CR17","unstructured":"OncoKB. https:\/\/www.oncokb.org\/"},{"key":"1732_CR18","unstructured":"COSMIC. https:\/\/cancer.sanger.ac.uk\/cosmic"},{"key":"1732_CR19","unstructured":"Cancer Hotspots. https:\/\/www.cancerhotspots.org\/."},{"key":"1732_CR20","first-page":"8","volume":"42","author":"S Kim","year":"2019","unstructured":"Kim S, Jeong S. Mutation hotspots in the \u03b2-catenin gene: lessons from the human cancer genome databases. Mol Cells. 2019;42:8\u201316.","journal-title":"Mol Cells"},{"key":"1732_CR21","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1158\/1078-0432.CCR-20-0479","volume":"26","author":"N Palanisamy","year":"2020","unstructured":"Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, et al. The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development. Clin Cancer Res. 2020;26:4933\u201346.","journal-title":"Clin Cancer Res"},{"key":"1732_CR22","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1038\/s41388-021-02008-9","volume":"40","author":"E Labanca","year":"2021","unstructured":"Labanca E, Bizzotto J, Sanchis P, Anselmino N, Yang J, Shepherd PDA, et al. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 2021;40:6284\u201398.","journal-title":"Oncogene"},{"key":"1732_CR23","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1126\/science.275.5307.1784","volume":"275","author":"V Korinek","year":"1997","unstructured":"Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. Constitutive transcriptional activation by a \u03b2-catenin-Tcf complex in APC \u2212\/\u2212 colon carcinoma. Science. 1997;275:1784\u20137.","journal-title":"Science"},{"key":"1732_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1078-0432.CCR-11-2521","volume":"18","author":"X Wan","year":"2012","unstructured":"Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, et al. Activation of \u03b2-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res. 2012;18:726\u201336.","journal-title":"Clin Cancer Res"},{"key":"1732_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/pros.22578","volume":"73","author":"A Vajda","year":"2013","unstructured":"Vajda A, Marignol L, Barrett C, Madden SF, Lynch TH, Hollywood D, et al. Gene expression analysis in prostate cancer: the importance of the endogenous control. Prostate. 2013;73:382\u201390.","journal-title":"Prostate"},{"key":"1732_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"1732_CR27","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1732_CR28","unstructured":"The Cancer Genome Atlas. TCGA. http:\/\/cancergenome.nih.gov\/."},{"key":"1732_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32701-6","volume":"13","author":"TC Westbrook","year":"2022","unstructured":"Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, et al. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022;13:5345.","journal-title":"Nat Commun"},{"key":"1732_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"1732_CR31","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein\u2013protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 2021;49:D605\u201312.","journal-title":"Nucleic Acids Res"},{"key":"1732_CR32","unstructured":"R Core Team. R: the R project for statistical computing. https:\/\/www.r-project.org\/"},{"key":"1732_CR33","unstructured":"RStudio Team. RStudio: integrated development environment for R. Boston. 2015. http:\/\/www.rstudio.com\/"},{"key":"1732_CR34","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation. 2021;2:100141.","journal-title":"Innovation"},{"key":"1732_CR35","doi-asserted-by":"publisher","unstructured":"Yu G. Enrichplot: visualization of functional enrichment result. https:\/\/doi.org\/10.18129\/B9.bioc.enrichplot, R package version 1.22.0, https:\/\/bioconductor.org\/packages\/enrichplot 2023.","DOI":"10.18129\/B9.bioc.enrichplot"},{"key":"1732_CR36","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44:D457\u201362.","journal-title":"Nucleic Acids Res"},{"key":"1732_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: a tool for the unification of biology. Nat Genet. 2000;25:25\u201329.","journal-title":"Nat Genet"},{"key":"1732_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 2011;12:77.","journal-title":"BMC Bioinforma"},{"key":"1732_CR39","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics"},{"key":"1732_CR40","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan L, Fran\u00e7ois R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4:1686.","journal-title":"J Open Source Softw"},{"key":"1732_CR41","doi-asserted-by":"publisher","unstructured":"Wickham H. ggplot2. Springer International Publishing: Cham; 2016. https:\/\/doi.org\/10.1007\/978-3-319-24277-4.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"1732_CR42","unstructured":"Alboukadel Kassambara. ggpubr: \u201cggplot2\u201d based publication-ready plots. 2023.https:\/\/rpkgs.datanovia.com\/ggpubr\/."},{"key":"1732_CR43","unstructured":"Neuwirth E. RColorBrewer: ColorBrewer Palettes 2022.https:\/\/CRAN.R-project.org\/package=RColorBrewer."},{"key":"1732_CR44","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461\u201373.","journal-title":"Oncogene"},{"key":"1732_CR45","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1242\/dev.033910","volume":"136","author":"R van Amerongen","year":"2009","unstructured":"van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development. 2009;136:3205\u201314.","journal-title":"Development"},{"key":"1732_CR46","doi-asserted-by":"publisher","first-page":"e74666","DOI":"10.1371\/journal.pone.0074666","volume":"8","author":"D Angonin","year":"2013","unstructured":"Angonin D, Van Raay TJ. Nkd1 functions as a passive antagonist of Wnt signaling. PLoS ONE. 2013;8:e74666.","journal-title":"PLoS ONE"},{"key":"1732_CR47","doi-asserted-by":"publisher","unstructured":"Kim WK, Buckley AJ, Lee DH, Hiroto A, Nenninger CH, Olson AW, et al. Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation. Nat Commun. 2024;15. https:\/\/doi.org\/10.1038\/s41467-024-45489-4.","DOI":"10.1038\/s41467-024-45489-4"},{"key":"1732_CR48","doi-asserted-by":"publisher","unstructured":"Ono M, Lai KKY, Wu K, Nguyen C, Lin DP, Murali R, et al. Nuclear receptor\/Wnt beta-catenin interactions are regulated via differential CBP\/ p300 coactivator usage. PLoS ONE. 2018;13. https:\/\/doi.org\/10.1371\/journal.pone.0200714.","DOI":"10.1371\/journal.pone.0200714"},{"key":"1732_CR49","doi-asserted-by":"publisher","unstructured":"Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, et al. Chromatin profiles classify castration-resistant prostate cancers, suggesting therapeutic targets. Science. 2022;376. https:\/\/doi.org\/10.1126\/science.abe1505.","DOI":"10.1126\/science.abe1505"},{"key":"1732_CR50","doi-asserted-by":"publisher","unstructured":"Khurana N, Sikka SC. Interplay between SOX9, Wnt\/\u03b2-catenin and androgen receptor signaling in castration-resistant prostate cancer. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20092066.","DOI":"10.3390\/ijms20092066"},{"key":"1732_CR51","doi-asserted-by":"publisher","first-page":"9918","DOI":"10.1158\/0008-5472.CAN-08-1718","volume":"68","author":"G Wang","year":"2008","unstructured":"Wang G, Wang J, Sadar MD. Crosstalk between the Androgen receptor and \u03b2-catenin in castrate-resistant prostate cancer. Cancer Res. 2008;68:9918\u201327.","journal-title":"Cancer Res"},{"key":"1732_CR52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12672-021-00396-8","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang C, Chen Q, Xu H. Wnt\/\u03b2-catenin signal transduction pathway in prostate cancer and associated drug resistance. Discov Oncol. 2021;12:2\u201312.","journal-title":"Discov Oncol"},{"key":"1732_CR53","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1210\/en.2008-0858","volume":"150","author":"R Singh","year":"2009","unstructured":"Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, et al. Regulation of myogenic differentiation by androgens: cross-talk between androgen receptor\u03b2-catenin and follistatin\/transforming growth factor-\u03b2 signaling pathways. Endocrinology. 2009;150:1259\u201368.","journal-title":"Endocrinology"},{"key":"1732_CR54","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1128\/MCB.00130-16","volume":"36","author":"I Crist\u00f3bal","year":"2016","unstructured":"Crist\u00f3bal I, Rojo F, Madoz-G\u00farpide J, Garc\u00eda-Foncillas J. Cross talk between Wnt\/\u03b2-catenin and CIP2A\/Plk1 signaling in prostate cancer: promising therapeutic implications. Mol Cell Biol. 2016;36:1734\u20139.","journal-title":"Mol Cell Biol"},{"key":"1732_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mce.2017.02.008","volume":"462","author":"JA Schneider","year":"2018","unstructured":"Schneider JA, Logan SK. Revisiting the role of Wnt\/\u03b2-catenin signaling in prostate cancer. Mol Cell Endocrinol. 2018;462:3\u20138.","journal-title":"Mol Cell Endocrinol"},{"key":"1732_CR56","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/jcb.20983","volume":"99","author":"S Terry","year":"2006","unstructured":"Terry S, Yang X, Chen M-W, Vacherot F, Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem. 2006;99:402\u201310.","journal-title":"J Cell Biochem"},{"key":"1732_CR57","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1073\/pnas.0701331104","volume":"104","author":"T Miyabayashi","year":"2007","unstructured":"Miyabayashi T, Teo J-L, Yamamoto M, McMillan M, Nguyen C, Kahn M. Wnt\/\u03b2-catenin\/CBP signaling maintains long-term murine embryonic stem cell pluripotency. Proc Natl Acad Sci. 2007;104:5668\u201373.","journal-title":"Proc Natl Acad Sci"},{"key":"1732_CR58","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1038\/sj.onc.1208433","volume":"24","author":"H Ma","year":"2005","unstructured":"Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP and p300 on TCF\/\u03b2-catenin-mediated survivin gene expression. Oncogene. 2005;24:3619\u201331.","journal-title":"Oncogene"},{"key":"1732_CR59","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1038\/onc.2015.438","volume":"35","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Masiello D, McMillian M, Nguyen C, Wu Y, Melendez E, et al. CBP\/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells. Oncogene. 2016;35:3705\u201317.","journal-title":"Oncogene"},{"key":"1732_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2020.10.013","volume":"23","author":"D Feng","year":"2021","unstructured":"Feng D, Yan K, Liang H, Liang J, Wang W, Yu H, et al. CBP-mediated Wnt3a\/\u03b2-catenin signaling promotes cervical oncogenesis initiated by Piwil2. Neoplasia. 2021;23:1\u201311.","journal-title":"Neoplasia"},{"key":"1732_CR61","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, et al. Targeting the p300\/CBP axis in lethal prostate cancer. Cancer Discov. 2021;11:1118\u201337.","journal-title":"Cancer Discov"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01732-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01732-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01732-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:14:34Z","timestamp":1776143674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01732-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":61,"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01732-7","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study used established human cell lines from qualified repositories. All practices involving animals were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center (MDACC), under the regulation of the Animal Welfare Committee and conform to the NIH Policy on Human Care and Use of Laboratory Animals (protocol: #00001091-RN03). The PDX models used in this study were generated by the MDA PCa PDX Program (pcapdxprogram@mdanderson.org) from prostate cancer tissue obtained during therapeutic or diagnostic procedures, including radical prostatectomies, orthopedic and neurosurgical interventions performed to palliate complications, and biopsies of metastatic lesions. Written informed consent was obtained from patients before sample acquisition, and all samples were processed according to a protocol approved by the Institutional Review Board of the University of Texas MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}